Avasimibe, a repurposed drug currently under clinical development, effectively blocks ACAT1, leading to an elevated anti-tumor response from CD8+ T cells and superior results when combined with anti-PD1 therapy (327). The gene discussed is CD8A; the disease is neoplasm.